Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Eoptolink Technology Inc.,
300502
5
Ningbo Bohui Chemical Technology
300839
CN Stock MarketDetailed Quotes
Shen Zhen Weiguang Biological Products (002880)
- 28.80
- -0.03-0.10%
Not Open Jul 15 15:00 CST
6.53BMarket Cap26.09P/E (TTM)
28.88High28.39Low16.73KlotVolume28.83Open28.83Prev Close47.97MTurnover0.74%Turnover Ratio25.76P/E (Static)226.80MShares33.5652wk High2.90P/B6.51BFloat Cap23.4352wk Low31.71Limit Up226.01MShs Float50.78Historical High25.95Limit Down1.70%Amplitude14.47Historical Low0.20Dividend TTM28.67Avg Price9.02KlotAsk0.69%Div Yield TTM100Lot Size7.24KlotBid
002880 Stock Chart
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
002880 Orderflow
Unit: --
002880 Orderflow Trend
IntradayDayWeekMonth
No Data
Shen Zhen Weiguang Biological Products (002880) News
Weiguang Biological Products Gets Approval to Produce Diagnostic Reagents
Shen Zhen Weiguang Biological Products (002880.SZ): Currently has 9 standalone blood plasma stations, all of which are now in Operation.
On April 30th, Gelonghui reported that Shen Zhen Weiguang Biological Products (002880.SZ) stated on the interactive platform that the company currently has 9 single-sourced plasma stations, all of which have been put into operation. The company will closely monitor market conditions and intensify efforts to apply for the establishment of single-sourced plasma stations to increase the scale of plasma collection.
Weiguang Biotech: Report for the first quarter of 2025
Weiguang Biotech: 2024 Annual Report Summary
Weiguang Biotech: 2024 Annual Report
Shen Zhen Weiguang Biological Products (002880.SZ) announced its performance for the fiscal year 2024, with a net income of 0.254 billion yuan, a year-on-year increase of 15.95%.
Shen Zhen Weiguang Biological Products (002880.SZ) released the annual report for 2024. During the reporting period, the company achieved revenue of 1...
Shen Zhen Weiguang Biological Products (002880) Stock Forum
The company's high P/E ratio and slower growth forecast may risk a share price decline. Investors might be overpaying for stock exposure, challenging to sustain with the earnings growth level.
Some Shareholders Feeling Restless Over Shenzhen Weiguang Biological Products Co., Ltd.'s (SZSE:002880) P/E RatioCaution is advised over Weiguang Biological Products due to reliance on unusual items for profits. Risks including warning signs must be understood before investing.
Market participants may hold the company in higher regard, considering its five-year track record of earnings growth. The total shareholder return in the last 5 years, at 77%, suggests that dividends have been beneficial for shareholders.
Read more
